Biodegradable Cationic Lipids for Gene Delivery
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current cationic lipids used for gene therapy suffer from sub-optimal delivery efficiency and toxicity, particularly at higher doses, limiting their efficacy and safety for repeated administration and treatment of genetic disorders.
Innovation Solution
Development of cationic lipids with a biodegradable hydrophobic tail and specific structural features, such as bifurcated hydrocarbon chains, that form stable lipid nanoparticles (LNPs) for enhanced nucleic acid delivery, offering improved encapsulation efficiency, expression levels, and tolerability.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If widely used cationic lipids (CLinDMA, DLinDMA, DOTAP) are employed for nucleic acid delivery, then delivery capability is achieved, but delivery efficiency remains sub-optimal and toxicity increases at higher doses
Solution Approach 1:
The patent modifies the chemical structure of cationic lipids by introducing biodegradable linkers (e.g., disulfide bonds, ester bonds, amide bonds) in the hydrophobic tail regions. This structural parameter change allows the lipids to degrade into less toxic components after delivering the nucleic acid payload, thereby reducing toxicity at higher doses while maintaining delivery efficiency. The biodegradable groups are strategically placed at different positions (alpha, omega, or both tails) to optimize both delivery performance and safety profile.
2Reliability
If viral vectors (rAAV) are used for gene delivery, then reliable gene delivery is achieved, but humoral and cellular immune responses compromise efficacy and prevent re-administration
Solution Approach 1:
The patent extracts and eliminates the immunogenic viral components (capsid proteins, viral genome) from the delivery system while retaining the essential gene delivery function through synthetic cationic lipid nanoparticles. By using non-viral cationic lipids with biodegradable tails, the system achieves gene delivery without triggering the humoral and cellular immune responses that characterize viral vector delivery, thereby enabling safe re-administration.
3Reliability
If cationic lipids with enhanced delivery efficiency are developed, then nucleic acid delivery improves, but synthesis complexity and purification difficulty increase
Solution Approach 1:
The patent segments the cationic lipid molecule into distinct functional modules: a cationic headgroup, a hydrophobic tail with biodegradable linkers, and optional terminal functional groups. This segmentation allows for modular synthesis where each component can be independently optimized and assembled. The biodegradable linkers are incorporated at specific positions (alpha or omega tails) to provide controlled degradation without requiring complex multi-step synthesis, thus balancing enhanced delivery efficiency with manufacturability.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The new cationic lipids provide sustained and stable in vivo expression of therapeutic nucleic acids with reduced toxicity, enabling repeated dosing and expanded patient access, including for rare genetic disorders, without eliciting significant immune responses.
Implementation Method 1
The cationic amine moiety and a polyanion nucleic acid interact electrostatically to form a positively charged liposome or lipid membrane structure
Data Source
AI summary
Provided herein are cationic lipids having the Formula I or la: and pharmaceutically acceptable salts thereof, wherein R′, R1, R2, R3, R4, R5, R6a, R6b, X, and n are as defined herein. Also provided herein are lipid nanoparticle (LNP) compositions comprising a cationic lipid having the Formula I or la and a capsid-free, non-viral vector (e.g., ceDNA). In one aspect of any of the aspects or embodiments herein, these LNPs can be used to deliver a capsid-free, non-viral DNA vector to a target site of interest (e.g., cell, tissue, organ, and the like).